Comparative Pharmacology
Head-to-head clinical analysis: CRESEMBA versus EXTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESEMBA versus EXTINA.
CRESEMBA vs EXTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isavuconazole, the active moiety of CRESEMBA, inhibits fungal cytochrome P450-dependent 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, disrupting fungal cell membrane synthesis and function.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
200 mg intravenously every 8 hours for the first 48 hours (6 doses), then 200 mg intravenously once daily; or 200 mg orally three times daily for the first 48 hours (6 doses), then 200 mg orally once daily.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, supporting once-daily dosing; steady-state achieved by Day 4-5.
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Fecal: ~76% (primarily as unchanged drug); Renal: <1% (unchanged); Biliary: Not a major route; Metabolism via CYP3A4 to inactive metabolites eliminated fecally.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Category C
Category C
Antifungal
Antifungal